Organon & Co. (OGN)
NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
As of 01:33PM EDT. Market open.
| Previous close | 18.42 |
| Open | 18.43 |
| Bid | 18.58 x 1100 |
| Ask | 18.59 x 900 |
| Day's range | 18.33 - 18.68 |
| 52-week range | 10.84 - 24.79 |
| Volume | |
| Avg. volume | 2,336,217 |
| Market cap | 4.733B |
| Beta (5Y monthly) | 0.79 |
| PE ratio (TTM) | 4.64 |
| EPS (TTM) | 3.99 |
| Earnings date | 02 May 2024 |
| Forward dividend & yield | 1.12 (6.08%) |
| Ex-dividend date | 23 Feb 2024 |
| 1y target est | 21.50 |
ZacksEarnings Preview: Organon (OGN) Q1 Earnings Expected to Decline
Organon (OGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Business WireOrganon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024
JERSEY CITY, N.J., April 08, 2024--Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024
Business WirePhase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints
SHANGHAI, China & JERSEY CITY, N.J., April 08, 2024--Organon and Henlius announce that Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoint
© 2024 Yahoo. All rights reserved.